引用次数
引用: 3,897
H-指数: 22
I10-指数 : 32
出版物: 87
MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic.
Frank J Slack , Andrea L Kasinski , Dean G Tang , Haifa Shen
Frontiers in Cell and Developmental Biology 9 640587 -640587
40
2021
Arresting the Culprit: Targeted Antagomir Delivery to Sequester Oncogenic miR-221 in HCC
Andrea L Kasinski , Frank J Slack
Molecular therapy. Nucleic acids 1 ( 3)
8
2012
MicroRNA therapeutics in preclinical cancer models.
Minlee Kim , Andrea L Kasinski , Frank J Slack
Lancet Oncology 12 ( 4) 319 -321
41
2011
RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes
Sean E Humphrey , Andrea L Kasinski
Journal of Hematology & Oncology 8 ( 1) 31 -31
8
2015
Loss of KMT5C promotes EGFR inhibitor resistance in NSCLC via LINC01510-mediated upregulation of MET
Arpita S Pal , Alejandra Agredo , Nadia A Lanman , Jihye Son
Cancer Research 82 ( 8) 1534 -1547
10
2022
Development of an RNA-based cancer therapeutic targeting the let-7-LIN28 interaction
Sunghyun Myoung , Sergey Savinov , Lan Chen , Gaurav Chopra
Cancer Research 78 ( 13_Supplement) 4656 -4656
2018
Inhibition of IKK-NF-κB signaling pathway by EF24, a novel monoketone analogue of curcumin
Andrea L Kasinski , Yuhong Du , Shala L Thomas , Jing Zhao
Molecular Pharmacology
7
2008
Correction for Puckett et al.,“Integration of Apoptosis Signal-Regulating Kinase 1-Mediated Stress Signaling with the Akt/Protein Kinase B-IκB Kinase Cascade”
Mary C Puckett , Erinn H Goldman , Lisa M Cockrell , Bei Huang
Molecular and Cellular Biology 42 ( 10)
2022
Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases
Ahmed M Abdelaal , Andrea L Kasinski
NAR cancer 3 ( 3) zcab030 -zcab030
21
2021
Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells
Humna Hasan , Ikjot Singh Sohal , Zulaida Soto-Vargas , Anjali M Byappanahalli
Scientific Reports 12 ( 1) 972 -972
19
2022
A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy
Ahmed M Abdelaal , Ikjot S Sohal , Shreyas Iyer , Kasireddy Sudarshan
Oncogene 42 ( 40) 2985 -2999
17
2023
Strategies for safe and targeted delivery of microRNA therapeutics
Sunghyun Sander Myoung , Andrea L Kasinski
12
2019
Emerging diversity in extracellular vesicles and their roles in cancer
Ikjot S Sohal , Andrea L Kasinski ,
Frontiers in Oncology 13 1167717 -1167717
7
2023
Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises
Wen Li , Yunfei Wang , Xiaozhuo Liu , Shan Wu
International Journal of Molecular Sciences 25 ( 4) 2123 -2123
2
2024
Ligand ionophore conjugates
Philip Stewart Low , Andrea L Kasinski , Loganathan Rangasamy , Venkatesh Chelvam
2
2019
Loss of the methyltransferase KMT5C drives resistance to tyrosine kinase inhibitors via H4K20me3 regulation in non-small cell lung cancer
Alejandra Agredo , Arpita Pal , Jihye Son , Nadia A Lanman
Cancer Research 83 ( 7_Supplement) 4752 -4752
1
2023
Uncovering mechanisms of biogenesis and secretion of small extracellular vesicles in non small cell lung cancer (NSCLC)
Zulaida M Soto Vargas , Ikjot Singh Sohal , Humna Hasan , David Arteaga
Cancer Research 82 ( 12_Supplement) 1581 -1581
1
2022
Aberrantly expressed microRNAs drive the development of acquired Erlotinib resistance in non-small cell lung cancer
Arpita S Pal , Alejandra Agredo , Andrea L Kasinski
Cancer Research 77 ( 13_Supplement) 3142 -3142
1
2017
Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent
Ahmed M Abdelaal , Ikjot S Sohal , Shreyas G Iyer , Kasireddy Sudarshan
Molecular Therapy-Nucleic Acids 35 ( 2)
2024
Preparing and Evaluating the Stability of Therapeutically Relevant Oligonucleotide Duplexes
Shreyas G Iyer , Andrea L Kasinski
Bio-protocol 14 ( 8)
2024